These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20576109)

  • 1. Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease.
    Stomrud E; Björkqvist M; Janciauskiene S; Minthon L; Hansson O
    Alzheimers Res Ther; 2010 Jun; 2(3):20. PubMed ID: 20576109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.
    Abe K; Chiba Y; Hattori S; Yoshimi A; Asami T; Katsuse O; Suda A; Hishimoto A;
    J Neurol Sci; 2020 Sep; 416():116989. PubMed ID: 32603972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma MMP-9/TIMP-1 ratio serves as a novel potential biomarker in Alzheimer's disease.
    Liu J; Li X; Qu J
    Neuroreport; 2023 Oct; 34(15):767-772. PubMed ID: 37695608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer's disease.
    Mroczko B; Groblewska M; Zboch M; Kulczyńska A; Koper OM; Szmitkowski M; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2014; 40(2):351-7. PubMed ID: 24448781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix Remodeling Enzymes as Potential Fluid Biomarkers of Neurodegeneration in Alzheimer's Disease.
    Bašić J; Milošević V; Djordjević B; Stojiljković V; Živanović M; Stefanović N; Aracki Trenkić A; Stojanov D; Jevtović Stoimenov T; Stojanović I
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex-specific associations of matrix metalloproteinases in Alzheimer's disease.
    Aksnes M; Edwin TH; Saltvedt I; Eldholm RS; Chaudhry FA; Halaas NB; Myrstad M; Watne LO; Knapskog AB
    Biol Sex Differ; 2023 May; 14(1):35. PubMed ID: 37221606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease.
    Bjerke M; Zetterberg H; Edman Å; Blennow K; Wallin A; Andreasson U
    J Alzheimers Dis; 2011; 27(3):665-76. PubMed ID: 21860087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases are associated with brain atrophy in cognitively unimpaired individuals.
    Aksnes M; Capogna E; Vidal-Piñeiro D; Chaudhry FA; Myrstad M; Idland AV; Halaas NB; Dakhil S; Blennow K; Zetterberg H; Walhovd KB; Watne LO; Fjell AM
    Neurobiol Aging; 2023 Nov; 131():11-23. PubMed ID: 37549446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
    Blom ES; Giedraitis V; Zetterberg H; Fukumoto H; Blennow K; Hyman BT; Irizarry MC; Wahlund LO; Lannfelt L; Ingelsson M
    Dement Geriatr Cogn Disord; 2009; 27(5):458-64. PubMed ID: 19420940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.
    Lautner R; Insel PS; Skillbäck T; Olsson B; Landén M; Frisoni GB; Herukka SK; Hampel H; Wallin A; Minthon L; Hansson O; Blennow K; Mattsson N; Zetterberg H
    Alzheimers Res Ther; 2017 Oct; 9(1):87. PubMed ID: 29061195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
    Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
    Wattmo C; Blennow K; Hansson O
    BMC Neurol; 2020 Jan; 20(1):10. PubMed ID: 31918679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
    Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
    Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds.
    Duits FH; Hernandez-Guillamon M; Montaner J; Goos JD; Montañola A; Wattjes MP; Barkhof F; Scheltens P; Teunissen CE; van der Flier WM
    J Alzheimers Dis; 2015; 48(3):711-20. PubMed ID: 26402072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyunsaturated Fatty Acid Composition of Cerebrospinal Fluid Fractions Shows Their Contribution to Cognitive Resilience of a Pre-symptomatic Alzheimer's Disease Cohort.
    Fonteh AN; Cipolla M; Chiang AJ; Edminster SP; Arakaki X; Harrington MG
    Front Physiol; 2020; 11():83. PubMed ID: 32116789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults.
    Paternicò D; Galluzzi S; Drago V; Bocchio-Chiavetto L; Zanardini R; Pedrini L; Baronio M; Amicucci G; Frisoni GB
    Alzheimers Dement; 2012 Nov; 8(6):520-7. PubMed ID: 22677492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.